Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis

BACKGROUND: Infliximab is a chimeric monoclonal antibody against tumour necrosis factor‐alpha for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Recently, a subcutaneous formulation of CT‐P13, an infliximab biosimilar, was approved for clinical use. AIMS: To characterise CT‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanzel, Jurij, Bukkems, Laura H., Gecse, Krisztina B., D’Haens, Geert R., Mathôt, Ron A. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Infliximab Biosimilar in IBD
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292975/
https://www.ncbi.nlm.nih.gov/pubmed/34559426
http://dx.doi.org/10.1111/apt.16609

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292975/
https://www.ncbi.nlm.nih.gov/pubmed/34559426
http://dx.doi.org/10.1111/apt.16609

Ejemplares similares